Comment on 'Existing Prognostic Models, but Not Neutrophil-to-lymphocyte Ratio, Are Prognostic in Malignant Mesothelioma'
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Ghanim B, Klikovits T, Hoda M, Lang G, Szirtes I, Setinek U Br J Cancer. 2015; 112(5):783-92.
PMID: 25633038 PMC: 4453963. DOI: 10.1038/bjc.2015.9.
Meniawy T, Creaney J, Lake R, Nowak A Br J Cancer. 2014; 111(12):2377.
PMID: 24714749 PMC: 4264421. DOI: 10.1038/bjc.2014.187.
References
1.
Kao S, Pavlakis N, Harvie R, Vardy J, Boyer M, van Zandwijk N
. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010; 16(23):5805-13.
DOI: 10.1158/1078-0432.CCR-10-2245.
View
2.
Pinato D, Stavraka C, Flynn M, Forster M, OCathail S, Seckl M
. An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One. 2014; 9(1):e83279.
PMC: 3883636.
DOI: 10.1371/journal.pone.0083279.
View
3.
Cedres S, Montero M, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D
. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer. 2012; 77(1):192-8.
DOI: 10.1016/j.lungcan.2012.02.022.
View
4.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P
. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44.
DOI: 10.1200/JCO.2003.11.136.
View
5.
Paramanathan A, Saxena A, Morris D
. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014; 23(1):31-9.
DOI: 10.1016/j.suronc.2013.12.001.
View